Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 7:5:1502285.
doi: 10.3389/falgy.2024.1502285. eCollection 2024.

Challenges in diagnosing polyethylene glycol and polysorbate 80 allergies: implications for allergic reactions in COVID-19 mRNA vaccination program: experience from Qatar

Sami Aqel  1 , Sherin Thalappil  1 , Asaad Imameldin  1 , Dalal Mudawi  1 , Muna Al Maslamani  2 , Abdullatif Al-Khal  2 , Hassan Mobayed  1 , Maryam Ali Al-Nesf  1 , Tayseer Ibrahim  1
Affiliations

Challenges in diagnosing polyethylene glycol and polysorbate 80 allergies: implications for allergic reactions in COVID-19 mRNA vaccination program: experience from Qatar

Sami Aqel et al. Front Allergy. .

Abstract

Introduction: COVID-19 vaccination has been a key intervention in reducing the severity of symptoms; however, concerns about vaccine safety, particularly regarding allergic reactions, arose early on. Healthcare workers faced the challenge of addressing these concerns to ensure safe vaccine administration. This study aimed to review the practical aspects of using allergy skin testing for COVID-19 vaccine excipients in patients with a history of allergic reactions developed following mRNA COVID-19 vaccination.

Methods: A retrospective chart review was conducted for patients who reported allergic reactions after the COVID-19 vaccine and underwent allergy skin testing for COVID-19 vaccine excipients in the Adult Allergy and Immunology Service at Hamad Medical Corporation, Doha, Qatar. The testing protocol, developed based on published data during the pandemic, included skin prick (SPT) and intradermal (ID) testing using medications containing polysorbate 80 and polyethylene glycol (PEG), the primary excipients in the COVID-19 vaccines suspected of triggering allergic responses.

Results: Of the 88 patients reviewed, 38 reported different types of allergic reactions following mRNA COVID-19 vaccination, with the majority being female. Anaphylaxis was reported in 21.1% of the patients, while the remaining experienced less severe allergic reactions. All patients underwent SPT and ID testing with PEG and polysorbate 80. By SPT, two patients tested positive for PEG and none for polysorbate 80. By ID, seven tested positive for polysorbate 80 and one for PEG. Among patients who experienced anaphylaxis, 50% had positive allergy test results. Twenty-three percent of patients with negative test results could receive additional vaccine doses without adverse reactions.

Conclusion: Managing patients with a history of allergic reactions to the COVID-19 vaccine is challenging, as the exact mechanisms and accurate and valid allergy testing are yet to be determined. In our cohort, most patients had mild allergic reactions following vaccination. Excipients' allergy skin testing has helped to reduce vaccine hesitancy despite its questionable utility in clinical practice.

Keywords: COVID-19 vaccines; Qatar; allergy testing; anaphylaxis; excipients; polyethylene glycol allergy; polysorbate allergy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the study of COVID-19 excipients allergy skin testing and outcome.
See this image and copyright information in PMC

References

    1. Dadras O, SeyedAlinaghi S, Karimi A, Shamsabadi A, Mahdiabadi S, Mohammadi P, et al. Public acceptability of COVID-19 vaccines and its predictors in Middle Eastern/North African (MENA) countries: a systematic review. Hum Vaccines Immunother. (2022) 18(5):2043719. 10.1080/21645515.2022.2043719 - DOI - PMC - PubMed
    1. Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. (2021) 326(14):1390. 10.1001/jama.2021.15072 - DOI - PMC - PubMed
    1. Paul P, Janjua E, AlSubaie M, Ramadorai V, Mushannen B, Vattoth AL, et al. Breathless encounters: analyzing anaphylaxis at the crossroads of COVID-19 vaccination. Qatar Med J. (2024) 2024(2):9. 10.5339/qmj.2024.qitc.9 - DOI - PMC - PubMed
    1. Almohaya AM, Alsubie H, Alqarni B, Alzayad B, Alghar A, Alshahrani K, et al. Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data. Vaccine. (2022) 40(3):477–82. 10.1016/j.vaccine.2021.12.001 - DOI - PMC - PubMed
    1. Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines. (2021) 9(6):556. 10.3390/vaccines9060556 - DOI - PMC - PubMed

LinkOut - more resources